Bovine Herpesvirus-4-Vectored Delivery of Nipah Virus Glycoproteins Enhances T Cell Immunogenicity in Pigs
Authors:
- Miriam PedreraMPMiriam Pedrera
- Francesca MacchiFMFrancesca Macchi
- Rebecca K. McLeanRMRebecca K. McLean
- Valentina FranceschiVFValentina Franceschi
- Nazia ThakurNTNazia Thakur
- Luca RussoLRLuca Russo
- Lobna MedfaiLMLobna Medfai
- Shawn ToddSTShawn Todd
- Elma Z. TchilianElma Z. Tchilian
- Jean-Christophe AudonnetJAJean-Christophe Audonnet
- Keith ChappellKCKeith Chappell
- Ariel IsaacsAIAriel Isaacs
Open Access
Abstract
Nipah virus (NiV) is an emergent pathogen capable of causing acute respiratory illness and fatal encephalitis in pigs and humans. A high fatality rate and broad host tropism makes NiV a serious public and animal health concern. There is therefore an urgent need for a NiV vaccines to protect animals and humans. In this study we investigated the immunogenicity of bovine herpesvirus (BoHV-4) vectors expressing either NiV attachment (G) or fusion (F) glycoproteins, BoHV-4-A-CMV-NiV-GΔTK or BoHV-4-A-CMV-NiV-FΔTK, respectively in pigs. The vaccines were benchmarked against a canarypox (ALVAC) vector expressing NiV G, previously demonstrated to induce protective immunity in pigs. Both BoHV-4 vectors induced robust antigen-specific antibody responses. BoHV-4-A-CMV-NiV-GΔTK stimulated NiV-neutralizing antibody titers comparable to ALVAC NiV G and greater than those induced by BoHV-4-A-CMV-NiV-FΔTK. In contrast, only BoHV-4-A-CMV-NiV-FΔTK immunized pigs had antibodies capable of significantly neutralizing NiV G and F-mediated cell fusion. All three vectored vaccines evoked antigen-specific CD4 and CD8 T cell responses, which were particularly strong in BoHV-4-A-CMV-NiV-GΔTK immunized pigs and to a lesser extent BoHV-4-A-CMV-NiV-FΔTK. These findings emphasize the potential of BoHV-4 vectors for inducing antibody and cell-mediated immunity in pigs and provide a solid basis for the further evaluation of these vectored NiV vaccine candidates.Keywords
This publication has 88 references indexed in Scilit:
- Bovine herpesvirus 4 glycoprotein B is indispensable for lytic replication and irreplaceable by VSVgBMC Veterinary Research, 2013
- Herpes simplex virus type 1 thymidine kinase–armed bovine herpesvirus type 4–based vector displays enhanced oncolytic properties in immunocompetent orthotopic syngenic mouse and rat glioma modelsNeuro-Oncology, 2012
- Vaccine Protection against Simian Immunodeficiency Virus in Monkeys Using Recombinant Gamma-2 HerpesvirusJournal of Virology, 2011
- A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challengeVaccine, 2011
- Profound early control of highly pathogenic SIV by an effector memory T-cell vaccineNature, 2011
- A Quantitative and Kinetic Fusion Protein-Triggering Assay Can Discern Distinct Steps in the Nipah Virus Membrane Fusion CascadeJournal of Virology, 2010
- Cellular Targeting of Engineered Heterologous Antigens Is a Determinant Factor for Bovine Herpesvirus 4-Based Vaccine Vector DevelopmentClinical and Vaccine Immunology, 2009
- Detuning CD8 T cells: down-regulation of CD8 expression, tetramer binding, and response during CTL activationJournal of Experimental Medicine, 2007
- Establishment of a Bovine Herpesvirus 4 based vector expressing a secreted form of the Bovine Viral Diarrhoea Virus structural glycoprotein E2 for immunization purposesBMC Biotechnology, 2007
- Recombinant Nipah Virus Vaccines Protect Pigs against ChallengeJournal of Virology, 2006